Business
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $268 million with Approximately 46,400 TRx Two Medicines Approved by the U.S. Food and Drug
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"INGREZZA® (valbenazine) Second Quarter Net Product Sales of $268 million with Approximately 46,400 TRx\n Two Medicines Approved by the U.S. Food and Drug Administration (FDA) During the Second Quarter, ONGENTYS® (opicapone) for Parkinson's Disease and ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) for Uterine Fibroids by AbbVie\n Strategic Partnership with Takeda on Seven Compounds Expands and Diversifies Research and Development Pipeline\n Single Phase III Global Registration Study of Crinecerfont in Adult Patients with Congenital Adrenal Hyperplasia Now Enrolling\n\n\nSAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance.\n\n \n \n \n \n \n \n\n \n\"I want to thank healthcare providers and our employees for the perseverance they showed during the second quarter to ensure patients had uninterrupted access to INGREZZA under the challenging circumstances caused by the COVID-19 pandemic. As we move into the second half of 2020, we remain focused on improving the diagnosis and treatment rates for people with tardive dyskinesia, preparing to make ONGENTYS available to people living with Parkinson's disease, and advancing our programs in clinical development,\" said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. \"With four U.S. FDA approved treatments that address four unique patient populations and a diverse and expanding pipeline, Neurocrine Biosciences is well positioned to be a leading neuroscience-focused biopharmaceutical company.\"\nFinancial Highlights\nThree Months EndedJune 30,\nSix Months EndedJune 30,\n(unaudited, in millions, except per share data)\n2020\n2019\n2020\n2019\nRevenues:\nINGREZZA product sales, net\n$\n267.6\n$\n180.5\n$\n498.7\n$\n316.9\nCollaboration revenue\n34.8\n3.0\n40.8\n5.0\nTotal revenues\n$\n302.4\n$\n183.5\n$\n539.5\n$\n321.9\nGAAP Research and Development (R&D)\n$\n80.9\n$\n61.7\n$\n139.2\n$\n99.4\nNon-GAAP R&D\n$\n51.0\n$\n45.7\n$\n101.6\n$\n78.0\nGAAP Selling, General and Administrative (SG&A)\n$\n96.5\n$\n80.8\n$\n214.3\n$\n168.3\nNon-GAAP SG&A\n$\n76.9\n$\n68.9\n$\n179.6\n$\n146.0\nGAAP net income (loss)\n$\n79.6\n$\n51.3\n$\n117.0\n$\n(50.8)\nGAAP net incom...